PL397167A1 - Przeciwnowotworowe bialko fuzyjne - Google Patents

Przeciwnowotworowe bialko fuzyjne

Info

Publication number
PL397167A1
PL397167A1 PL397167A PL39716711A PL397167A1 PL 397167 A1 PL397167 A1 PL 397167A1 PL 397167 A PL397167 A PL 397167A PL 39716711 A PL39716711 A PL 39716711A PL 397167 A1 PL397167 A1 PL 397167A1
Authority
PL
Poland
Prior art keywords
domain
fusion protein
amino acid
sequence
fragment
Prior art date
Application number
PL397167A
Other languages
English (en)
Inventor
Jerzy Szczepan Pieczykolan
Sebastian Dominik Pawlak
Bartłomiej Żerek
Michał Szymanik
Anna Maria Pieczykolan
Piotr Kamil Rózga
Urszula Marta Szawłowska
Albert Robert Jaworski
Małgorzata Izabela Teska-Kamińska
Original Assignee
Adamed Spólka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Spólka Z Ograniczona Odpowiedzialnoscia filed Critical Adamed Spólka Z Ograniczona Odpowiedzialnoscia
Priority to PL397167A priority Critical patent/PL397167A1/pl
Priority to IN4498CHN2014 priority patent/IN2014CN04498A/en
Priority to SG11201402312WA priority patent/SG11201402312WA/en
Priority to CN201280058346.6A priority patent/CN103974711A/zh
Priority to AU2012345494A priority patent/AU2012345494A1/en
Priority to HK15102260.2A priority patent/HK1201727A1/xx
Priority to BR112014012808A priority patent/BR112014012808A2/pt
Priority to US14/361,279 priority patent/US20150044162A1/en
Priority to KR1020147018001A priority patent/KR20140097529A/ko
Priority to PCT/IB2012/056806 priority patent/WO2013080147A2/en
Priority to CA2856480A priority patent/CA2856480A1/en
Priority to EP12816127.0A priority patent/EP2785362A2/en
Priority to JP2014544020A priority patent/JP2015500228A/ja
Priority to EA201491049A priority patent/EA201491049A1/ru
Priority to MX2014006369A priority patent/MX2014006369A/es
Publication of PL397167A1 publication Critical patent/PL397167A1/pl
Priority to PH12014501083A priority patent/PH12014501083A1/en
Priority to IL232743A priority patent/IL232743A0/en
Priority to ZA2014/04667A priority patent/ZA201404667B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Wynalazek dotyczy dziedziny terapeutycznych bialek fuzyjnych, zwlaszcza rekombinowanych bialek fuzyjnych. Bialko fuzyjne zawiera domene (a), która jest funkcjonalny fragment sekwencji bialka hTRAIL rozpoczynajacy sie aminokwasem w pozycji nie nizszej niz hTRAIL95, i konczacy sie aminokwasem hTRAIL281, lub homolog wspomnianego funkcjonalnego fragmentu hTRAIL o sekwencji aminokwasów przynajmniej w 85% identycznej z tym fragmentem; i przynajmniej jedna domene (b) stanowiaca sekwencje peptydu efektorowego o dzialaniu hamujacym synteze bialka wewnatrz komórki, przy czym sekwencja domeny (b) jest przylaczona na C-koncu i/lub N-koncu domeny (a), bialko fuzyjne nie posiada domeny wiazacej sie z receptorami weglowodanowymi na powierzchni komórki. Bialko fuzyjne znajduje zastosowania w leczeniu chorób nowotworowych.
PL397167A 2011-11-28 2011-11-28 Przeciwnowotworowe bialko fuzyjne PL397167A1 (pl)

Priority Applications (18)

Application Number Priority Date Filing Date Title
PL397167A PL397167A1 (pl) 2011-11-28 2011-11-28 Przeciwnowotworowe bialko fuzyjne
PCT/IB2012/056806 WO2013080147A2 (en) 2011-11-28 2012-11-28 Anticancer fusion protein
CA2856480A CA2856480A1 (en) 2011-11-28 2012-11-28 Anticancer fusion protein
CN201280058346.6A CN103974711A (zh) 2011-11-28 2012-11-28 抗癌融合蛋白
AU2012345494A AU2012345494A1 (en) 2011-11-28 2012-11-28 Anticancer fusion protein
HK15102260.2A HK1201727A1 (en) 2011-11-28 2012-11-28 Anticancer fusion protein
BR112014012808A BR112014012808A2 (pt) 2011-11-28 2012-11-28 proteína de fusão anticâncer
US14/361,279 US20150044162A1 (en) 2011-11-28 2012-11-28 Anticancer fusion protein
KR1020147018001A KR20140097529A (ko) 2011-11-28 2012-11-28 항암 융합 단백질
IN4498CHN2014 IN2014CN04498A (pl) 2011-11-28 2012-11-28
SG11201402312WA SG11201402312WA (en) 2011-11-28 2012-11-28 Anticancer fusion protein
EP12816127.0A EP2785362A2 (en) 2011-11-28 2012-11-28 Anticancer fusion protein
JP2014544020A JP2015500228A (ja) 2011-11-28 2012-11-28 抗がん融合タンパク質
EA201491049A EA201491049A1 (ru) 2011-11-28 2012-11-28 Противораковый слитый белок
MX2014006369A MX2014006369A (es) 2011-11-28 2012-11-28 Proteina de fusion anticancerigena.
PH12014501083A PH12014501083A1 (en) 2011-11-28 2014-05-14 Anticancer fusion protein
IL232743A IL232743A0 (en) 2011-11-28 2014-05-21 anticancer fusion protein
ZA2014/04667A ZA201404667B (en) 2011-11-28 2014-06-25 Anticancer fusion protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL397167A PL397167A1 (pl) 2011-11-28 2011-11-28 Przeciwnowotworowe bialko fuzyjne

Publications (1)

Publication Number Publication Date
PL397167A1 true PL397167A1 (pl) 2013-06-10

Family

ID=47561689

Family Applications (1)

Application Number Title Priority Date Filing Date
PL397167A PL397167A1 (pl) 2011-11-28 2011-11-28 Przeciwnowotworowe bialko fuzyjne

Country Status (18)

Country Link
US (1) US20150044162A1 (pl)
EP (1) EP2785362A2 (pl)
JP (1) JP2015500228A (pl)
KR (1) KR20140097529A (pl)
CN (1) CN103974711A (pl)
AU (1) AU2012345494A1 (pl)
BR (1) BR112014012808A2 (pl)
CA (1) CA2856480A1 (pl)
EA (1) EA201491049A1 (pl)
HK (1) HK1201727A1 (pl)
IL (1) IL232743A0 (pl)
IN (1) IN2014CN04498A (pl)
MX (1) MX2014006369A (pl)
PH (1) PH12014501083A1 (pl)
PL (1) PL397167A1 (pl)
SG (1) SG11201402312WA (pl)
WO (1) WO2013080147A2 (pl)
ZA (1) ZA201404667B (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111363047A (zh) 2013-03-12 2020-07-03 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
ES2749862T3 (es) 2014-01-27 2020-03-24 Molecular Templates Inc Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
ES2864124T3 (es) * 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
KR102496206B1 (ko) * 2014-06-11 2023-02-06 몰레큘러 템플레이츠, 인코퍼레이션. 프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
WO2016126950A1 (en) 2015-02-05 2016-08-11 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
CN114656573B (zh) * 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
CN112574316A (zh) 2015-07-02 2021-03-30 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
KR101732126B1 (ko) 2015-11-05 2017-05-02 한국생명공학연구원 췌장암 치료용 융합 단백질 및 이의 용도
PL233352B1 (pl) * 2016-09-15 2019-10-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe białko fuzyjne
MX2019006656A (es) 2016-12-07 2019-09-09 Molecular Templates Inc Polipeptidos efectores de la sub-unidad a de la toxina shiga andamiajes de los efectores de la toxina shiga y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
CN106632680A (zh) * 2016-12-27 2017-05-10 上海交通大学 植物体系表达人源化抗agr2单克隆抗体18a4的质粒构建
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
EP3762401A4 (en) * 2018-03-06 2021-12-08 The Johns Hopkins University CANCER TREATMENT OR PREVENTION METHODS USING TREG DEPLETING AGENT AND CHECKPOINT INHIBITOR
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
EP3984546A4 (en) * 2019-05-15 2023-09-27 Universidad de Granada Gene therapy with the genes hokd and ldrb for cancer treatments
CN113354738B (zh) * 2020-03-05 2022-09-09 绍兴德方华生物技术有限公司 融合毒素VEGF165b/mGEL及其编码基因与应用
WO2022038152A1 (en) * 2020-08-17 2022-02-24 Atb Therapeutics Recombinant immunotoxin comprising a ribotoxin or rnase
CN114681599B (zh) * 2020-12-31 2024-07-02 中国科学院上海药物研究所 一种阳离子脂质体疫苗及其制备方法和用途
CN117795081A (zh) * 2021-08-06 2024-03-29 花王株式会社 利用snare的核酸构建体
CN117384859B (zh) * 2023-12-13 2024-03-22 北京翊博生物集团有限公司 一种树突状细胞来源的外泌体的制备方法及应用
CN118792375B (zh) * 2024-06-25 2025-09-23 华南农业大学 一种具有补肾壮阳功效的瓜蒌多肽及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225378C (en) 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
AU2001238501A1 (en) 2000-02-16 2001-08-27 Bechtel Bwxt Idaho, Llc Selective destruction of cells infected with human immunodeficiency virus
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
CN1257187C (zh) * 2003-10-22 2006-05-24 上海恰尔生物技术有限公司 钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
CA2544473C (en) 2003-11-03 2013-08-13 Beijing Sunbio Biotech Co., Ltd. A recombinant protein having an anti-cancer effect, its encoding gene and uses thereof
US7252993B2 (en) 2004-03-12 2007-08-07 Battelle Energy Alliance, Llc Plasmids encoding therapeutic agents
ATE524489T1 (de) 2005-07-29 2011-09-15 Us Gov Health & Human Serv Mutierte pseudomonas-exotoxine mit reduzierter antigenität
BRPI0615997A8 (pt) 2005-08-16 2018-05-22 Genentech Inc método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção
WO2008052322A1 (en) 2006-10-30 2008-05-08 Viventia Biotech Inc. Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers
JP4954293B2 (ja) 2006-12-29 2012-06-13 オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド 改変毒素を選択および生産する方法、改変毒素を含む複合体、およびそれらの使用
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2009094634A1 (en) * 2008-01-24 2009-07-30 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same
WO2009140469A2 (en) 2008-05-14 2009-11-19 Genentech, Inc. Methods of using apo2l/trail to treat cancer
CN102137869B (zh) * 2008-06-30 2018-07-06 宾夕法尼亚大学 Fn14/TRAIL融合蛋白

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate

Also Published As

Publication number Publication date
MX2014006369A (es) 2014-07-09
ZA201404667B (en) 2015-09-30
HK1201727A1 (en) 2015-09-11
AU2012345494A1 (en) 2014-07-10
KR20140097529A (ko) 2014-08-06
EP2785362A2 (en) 2014-10-08
WO2013080147A2 (en) 2013-06-06
US20150044162A1 (en) 2015-02-12
BR112014012808A2 (pt) 2019-09-24
SG11201402312WA (en) 2014-06-27
JP2015500228A (ja) 2015-01-05
EA201491049A1 (ru) 2014-10-30
IN2014CN04498A (pl) 2015-09-11
IL232743A0 (en) 2014-07-31
CN103974711A (zh) 2014-08-06
PH12014501083A1 (en) 2014-08-04
WO2013080147A3 (en) 2014-02-13
CA2856480A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
EA201491049A1 (ru) Противораковый слитый белок
BR112015020587A2 (pt) proteínas de fusão de apelina e suas utilizações
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
MX377692B (es) Peptidos anti-inflamatorios y usos de los mismos.
PH12018502451A1 (en) Brain delivery protein
NZ610075A (en) Cxcr2 binding polypeptides
BR112013013548B8 (pt) Proteína de fusão anticancerígena
MX380658B (es) Variantes de region fc con union mejorada de la proteina a.
PL397595A1 (pl) Przeciwnowotworowe bialko fuzyjne
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
MX356433B (es) Polipéptidos de fusión con domino de proteína ácida del suero, y métodos de uso de los mismos.
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
MX343386B (es) Proteinas de fusion portadoras de peptido como vacunas para alergia.
NZ724196A (en) Uti fusion proteins
EP2403871A4 (en) FOR ABUSED PRION PROTEIN SPECIFIC ANTIBODIES AND EPITOPES
MX2025010859A (es) Polipéptidos de fusión dap10/dap12.
HRP20210635T1 (hr) Novi mutant humanog seruma albumina
EA201391546A1 (ru) Противораковый слитый белок
NZ706202A (en) Peptide antagonists of the vasopressin-2 receptor
BR112013011285A2 (pt) vacina
WO2015134833A3 (en) Therapeutic proteins for treating cancers and methods for using such proteins
LV15035A (lv) Rekombinēta himēriska polipeptīda, kas satur melanokortīna otrā tipa receptoru (MC2R) un melanokortīnu receptoru palīgproteīnu (MRAP), kDNS secības, un tās izmantošana aktīvo vielu testēšanai un terapeitiskiem mērķiem